Goes FS. Genetics of Bipolar Disorder: Recent Update and Future Directions. Psychiatr Clin North Am. 2016 Mar. 39 (1):139-55. [Medline].
Kerner B. Toward a Deeper Understanding of the Genetics of Bipolar Disorder. Front Psychiatry. 2015. 6:105. [Medline].
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Association; 2013.
Shih RA, Belmonte PL, Zandi PP. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry. 2004 Nov. 16(4):260-83. [Medline].
Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002. 7(4):405-11. [Medline].
Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet. 2003 Jul. 73(1):49-62. [Medline]. [Full Text].
McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet. 2005 Oct. 77(4):582-95. [Medline]. [Full Text].
Abou Jamra R, Schulze TG, Becker T, Brockschmidt FF, Green E, Alblas MA, et al. A systematic association mapping on chromosome 6q in bipolar affective disorder--evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2010 Jun 5. 153B(4):878-84. [Medline].
Wang S, Behan J, O'Neill K, Weig B, Fried S, Laz T, et al. Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, mch-r2. J Biol Chem. 2001 Sep 14. 276(37):34664-70. [Medline].
Fan J, Ionita-Laza I, McQueen MB, Devlin B, Purcell S, Faraone SV, et al. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5. 153B(1):29-37. [Medline].
Badner JA, Koller D, Foroud T, Edenberg H, Nurnberger JI Jr, Zandi PP, et al. Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. Mol Psychiatry. 2012 Jul. 17(8):818-26. [Medline]. [Full Text].
Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet. 2006 Jun. 14(6):660-8. [Medline].
Hayden EP, Nurnberger JI Jr. Molecular genetics of bipolar disorder. Genes Brain Behav. 2006 Feb. 5(1):85-95. [Medline].
Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry. 2003 Jul. 8(7):646-53. [Medline].
Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H, et al. Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol Psychiatry. 2005 Aug. 10(8):771-81. [Medline].
Jiang HY, Qiao F, Xu XF, Yang Y, Bai Y, Jiang LL. Meta-analysis confirms a functional polymorphism (5-HTTLPR) in the serotonin transporter gene conferring risk of bipolar disorder in European populations. Neurosci Lett. 2013 Aug 9. 549:191-6. [Medline].
Mansour HA, Monk TH, Nimgaonkar VL. Circadian genes and bipolar disorder. Ann Med. 2005. 37(3):196-205. [Medline].
Nievergelt CM, Kripke DF, Barrett TB, Burg E, Remick RA, Sadovnick AD, et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2006 Apr 5. 141B(3):234-41. [Medline]. [Full Text].
Shi J, Wittke-Thompson JK, Badner JA, Hattori E, Potash JB, Willour VL, et al. Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5. 147B(7):1047-55. [Medline]. [Full Text].
Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipolar Disord. 2010 Aug. 12(5):459-72. [Medline].
Yin L, Wang J, Klein PS, Lazar MA. Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science. 2006 Feb 17. 311(5763):1002-5. [Medline].
McCarthy MJ, Nievergelt CM, Kelsoe JR, Welsh DK. A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response. PLoS One. 2012. 7(2):e32091. [Medline]. [Full Text].
McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007 Aug. 17(8):605-17. [Medline].
Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007 Apr 10. 104(15):6406-11. [Medline]. [Full Text].
Abou Jamra R, Becker T, Georgi A, Feulner T, Schumacher J, Stromaier J, et al. Genetic variation of the FAT gene at 4q35 is associated with bipolar affective disorder. Mol Psychiatry. 2008 Mar. 13(3):277-84. [Medline].
Blair IP, Chetcuti AF, Badenhop RF, Scimone A, Moses MJ, Adams LJ, et al. Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Mol Psychiatry. 2006 Apr. 11(4):372-83. [Medline].
Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci. 2002 Jun. 20(2):257-70. [Medline].
Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A. 2008 Jan 29. 105(4):1333-8. [Medline]. [Full Text].
Ortega F, Pérez-Sen R, Morente V, Delicado EG, Miras-Portugal MT. P2X7, NMDA and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons. Cell Mol Life Sci. 2010 May. 67(10):1723-33. [Medline]. [Full Text].
Liu L, Foroud T, Xuei X, Berrettini W, Byerley W, Coryell W, et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr Genet. 2008 Dec. 18 (6):267-74. [Medline].
Wang Z, Li Z, Gao K, Fang Y. Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis. BMC Psychiatry. 2014 Dec 24. 14:366. [Medline].
Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008 Jan 11. 132(1):125-36. [Medline].
Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet. 2002 Sep. 71(3):651-5. [Medline]. [Full Text].
Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim Y-, Tsan G, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry. 2002. 7(6):579-93. [Medline].
Müller DJ, de Luca V, Sicard T, King N, Strauss J, Kennedy JL. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry. 2006 Oct. 189:317-23. [Medline].
Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A, Novak T, et al. Increase in GSK3beta gene copy number variation in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5. 144B(3):259-65. [Medline].
O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, et al. Glycogen synthase kinase-3 is essential for ß-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest. 2011 Sep. 121(9):3756-62. [Medline]. [Full Text].
Lango H, Weedon MN. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice?. J Intern Med. 2008 Jan. 263(1):16-27. [Medline].
Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landén M, et al. Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet. 2016 Jun 21. [Medline].
Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008 Feb. 13(2):197-207. [Medline]. [Full Text].
Zeng Z, Wang T, Li T, Li Y, Chen P, Zhao Q, et al. Common SNPs and haplotypes in DGKH are associated with bipolar disorder and schizophrenia in the Chinese Han population. Mol Psychiatry. 2011 May. 16(5):473-5. [Medline].
Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008 Jun. 13(6):558-69. [Medline]. [Full Text].
Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011 Sep 18. 43(10):977-83. [Medline]. [Full Text].
Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008 Sep. 40 (9):1056-8. [Medline].
Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E, et al. Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. Mol Psychiatry. 2013 Dec. 18 (12):1302-7. [Medline].
Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A. 2009 May 5. 106(18):7501-6. [Medline]. [Full Text].
Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry. 2009 Aug. 14(8):755-63. [Medline]. [Full Text].
Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014 Mar 11. 5:3339. [Medline].
Xu W, Cohen-Woods S, Chen Q, Noor A, Knight J, Hosang G, et al. Genome-wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1. BMC Med Genet. 2014 Jan 4. 15:2. [Medline]. [Full Text].
Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum Psychopharmacol. 2002 Oct. 17(7):321-7. [Medline].
Squassina A, Manchia M, Congiu D, Severino G, Chillotti C, Ardau R, et al. The diacylglycerol kinase eta gene and bipolar disorder: a replication study in a Sardinian sample. Mol Psychiatry. 2009 Apr. 14(4):350-1. [Medline].
Manchia M, Squassina A, Congiu D, Chillotti C, Ardau R, Severino G, et al. Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neurosci Lett. 2009 Dec 25. 467(2):67-71. [Medline].
Zhou D, Lambert S, Malen PL, Carpenter S, Boland LM, Bennett V. AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing. J Cell Biol. 1998 Nov 30. 143 (5):1295-304. [Medline].
Ruberto G, Vassos E, Lewis CM, Tatarelli R, Girardi P, Collier D, et al. The cognitive impact of the ANK3 risk variant for bipolar disorder: initial evidence of selectivity to signal detection during sustained attention. PLoS One. 2011 Jan 31. 6(1):e16671. [Medline]. [Full Text].
Cottrell JR, Borok E, Horvath TL, Nedivi E. CPG2: a brain- and synapse-specific protein that regulates the endocytosis of glutamate receptors. Neuron. 2004 Nov 18. 44(4):677-90. [Medline]. [Full Text].
Loebrich S, Djukic B, Tong ZJ, Cottrell JR, Turrigiano GG, Nedivi E. Regulation of glutamate receptor internalization by the spine cytoskeleton is mediated by its PKA-dependent association with CPG2. Proc Natl Acad Sci U S A. 2013 Nov 19. 110(47):E4548-56. [Medline]. [Full Text].
Bigos KL, Mattay VS, Callicott JH, Straub RE, Vakkalanka R, Kolachana B, et al. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry. 2010 Sep. 67(9):939-45. [Medline]. [Full Text].
Perrier E, Pompei F, Ruberto G, Vassos E, Collier D, Frangou S. Initial evidence for the role of CACNA1C on subcortical brain morphology in patients with bipolar disorder. Eur Psychiatry. 2011 Apr. 26(3):135-7. [Medline].
Schlecker C, Boehmerle W, Jeromin A, DeGray B, Varshney A, Sharma Y, et al. Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. J Clin Invest. 2006 Jun. 116(6):1668-74. [Medline]. [Full Text].
Shi J, Badner JA, Gershon ES, Liu C. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res. 2008 Jan. 98(1-3):89-97. [Medline]. [Full Text].
Müller DJ, Zai CC, Shinkai T, Strauss J, Kennedy JL. Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disord. 2011 Mar. 13(2):198-207. [Medline].
Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000 May 22. 9(9):1415-23. [Medline].
Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J, et al. Family-based association study of lithium-related and other candidate genes in bipolar disorder. Arch Gen Psychiatry. 2008 Jan. 65(1):53-61. [Medline].
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007 Jun 7. 447(7145):661-78. [Medline]. [Full Text].
O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008 Sep. 40 (9):1053-5. [Medline].
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry. 2011 Apr. 16(4):429-41. [Medline]. [Full Text].
Lett TA, Zai CC, Tiwari AK, Shaikh SA, Likhodi O, Kennedy JL, et al. ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. World J Biol Psychiatry. 2011 Aug. 12(5):392-7. [Medline].
Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S, et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet. 2011 Jan 15. 20(2):387-91. [Medline].
Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull. 2009 May. 35(3):482-90. [Medline]. [Full Text].
Labbe A, Bureau A, Moreau I, Roy MA, Chagnon Y, Maziade M, et al. Symptom dimensions as alternative phenotypes to address genetic heterogeneity in schizophrenia and bipolar disorder. Eur J Hum Genet. 2012 Nov. 20(11):1182-8. [Medline]. [Full Text].
Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL,. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2013 Nov 26. [Medline].
Severino G, Squassina A, Costa M, Pisanu C, Calza S, Alda M, et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013 Apr. 14(6):655-74. [Medline].
Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry. 2001 Jun. 58(6):539-44. [Medline].
Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord. 2010 Nov. 12(7):702-6. [Medline].
Frye MA, McElroy SL, Prieto ML, Harper KL, Walker DL, Kung S, et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry. 2015 Feb. 76 (2):174-80. [Medline].
Biernacka JM, McElroy SL, Crow S, Sharp A, Benitez J, Veldic M, et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord. 2012 Jan. 136 (1-2):e21-9. [Medline].
Smith DJ, Evans R, Craddock N. Predicting response to lithium in bipolar disorder: a critical review of pharmacogenetic studies. J Ment Health. 2010 Apr. 19(2):142-56. [Medline].
Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics. 2010 Aug 3. 2010:159761. [Medline]. [Full Text].
Ewald H, Wang AG, Vang M, Mors O, Nyegaard M, Kruse TA. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr Genet. 1999 Mar. 9(1):23-34. [Medline].
Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, Marineau C, et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry. 2001 Sep. 6(5):570-8. [Medline].
Proft F, Kopf J, Olmes D, Hempel S, Schmidt B, Riederer P, et al. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome. Pharmacopsychiatry. 2014 Nov. 47 (7):245-50. [Medline].
Perlis RH, Adams DH, Fijal B, Sutton VK, Farmen M, Breier A, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010 May. 71(5):599-605. [Medline].
Kim B, Kim CY, Lee MJ, Joo YH. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 2009 Aug 15. 168(3):209-12. [Medline].
Dávila R, Zumárraga M, Basterreche N, Arrúe A, Zamalloa MI, Anguiano JB. Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report. J Affect Disord. 2006 Jun. 92(2-3):277-81. [Medline].
Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009 Jun. 166(6):718-25. [Medline]. [Full Text].
Squassina A, Manchia M, Borg J, Congiu D, Costa M, Georgitsi M, et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011 Nov. 12(11):1559-69. [Medline].
Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014 Jan 9. 370(2):119-28. [Medline].
Ikeda M, Kondo K, Iwata N. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014 May 8. 370 (19):1856-7. [Medline].
Consortium on Lithium Genetics., Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014 May 8. 370 (19):1857-9. [Medline].
Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016 Mar 12. 387 (10023):1085-93. [Medline].
Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, et al. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). Pharmacogenomics J. 2014 Apr. 14 (2):182-91. [Medline].
Fabbri C, Serretti A. Genetics of long-term treatment outcome in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4. 65:17-24. [Medline].
Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet. 2002 Sep. 71(3):651-5. [Medline]. [Full Text].
Zhang D, Cheng L, Qian Y, Alliey-Rodriguez N, Kelsoe JR, Greenwood T, et al. Singleton deletions throughout the genome increase risk of bipolar disorder. Mol Psychiatry. 2009 Apr. 14(4):376-80. [Medline]. [Full Text].
Schizophrenia Working Group of the Psychiatric Genomics Consortium; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium; Cross-Disorder Working Group of the Psychiatric Genomics Consortium. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2013 Nov 26. [Medline].
Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry. 2009 Aug. 14(8):755-63. [Medline]. [Full Text].